JPRN-UMIN000040704已完成未知
EJ049 study - NEJ049
orth East Japan Study Group (NEJSG)0 个研究点目标入组 300 人开始时间: 2020年6月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) LCNEC and Combined SCLC
研究者
相似试验
已完成
2 期
To study the outcomes of a new modification of jejuno-ileal bypass bariatric surgeryObesity.Factors influencing health status and contact with healthZ40-Z45IRCT2014020216322N2AJA University of Medical Sciences200
进行中（未招募）
1 期
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell non-Hodgkin Lymphoma (r/r B-NHL)on-Hodgkin Lymphoid MalignanciesCancerISRCTN17666983Janssen-Cilag International NV92
已完成
不适用
Japanese multicenter REsearch of COVID-19 by assEmbling Real-world dataCOVID-19JPRN-UMIN000047056ippon Medical School Musashikosugi Hospital4,700
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaCTIS2023-506588-32-00Janssen - Cilag International397
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaRelapsed and lenalidomide-refractory multiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-001413-16-BEJanssen-Cilag International NV400